Pricing & Access· June 30, 2026 · 18 min read
China's 2026 Dual-Track Drug Catalog: Reading NHSA Preliminary Numbers
By Ran Chen#China#Market Access#Drug Pricing
Topic
Formulary Strategy
Tiering, exclusions, preferred products, step therapy, and how access teams prepare the evidence packet.
Policy· June 30, 2026 · 18 min read
FDA Market Exclusivity by the Numbers: Exclusivity and GAIN Registry Analysis
By Ran Chen#Orange Book#Generics#Generic Entry
Generics· June 25, 2026 · 19 min read
Generic Forteo: Drug-Device Pathways and PBM Exclusions
By Ran Chen#Generics#Orange Book#505(b)(2)
Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Policy· June 21, 2026 · 5 min read
Building the AMCP dossier: a guide to the version 5.0 format and value evidence template
Biosimilars· June 16, 2026 · 11 min read
Interchangeable biosimilars in the Purple Book: 46 products, 12 reference biologics
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Pricing & Access· June 13, 2026 · 14 min read
NADAC price lookup: what acquisition-cost data can and cannot say about payer spread
Pricing & Access· June 12, 2026 · 9 min read
CMS NADAC by the numbers: 696K records, median $0.19/unit, brands 81× generic
By Ran Chen#Drug Pricing#Medicaid#Formulary Strategy
Biosimilars· June 10, 2026 · 8 min read
Biosimilar competition decoded: 229 products across 20 reference drugs, one concentration
By Ran Chen#Biosimilars#Purple Book#Formulary Strategy
Policy· June 10, 2026 · 9 min read